<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Cerebrovascular disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) is a global public health problem </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> patients are at high risk of recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo> and other atherothrombotic events </plain></SENT>
<SENT sid="2" pm="."><plain>Prevalence of risk factors, comorbidities, utilization of secondary prevention therapies and adherence to guidelines <z:hpo ids='HP_0000001'>all</z:hpo> influence the recurrent event rate </plain></SENT>
<SENT sid="3" pm="."><plain>We assessed these factors in 18,992 CVD patients within a worldwide registry of stable outpatients </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: The Reduction of Atherothrombosis for Continued Health Registry recruited &gt;68,000 outpatients (44 countries) </plain></SENT>
<SENT sid="5" pm="."><plain>The subjects were mainly recruited by general practitioners (44%) and internists (29%) if they had symptomatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, <z:hpo ids='HP_0004950'>peripheral arterial disease</z:hpo> (PAD) and/or &gt;or=3 atherothrombotic risk factors </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The 18,992 CVD patients suffered a <z:hpo ids='HP_0001297'>stroke</z:hpo> (53.7%), <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> (<z:hpo ids='HP_0002326'>TIA</z:hpo>) (27.7%) or both (18.5%); 40% had symptomatic atherothrombotic disease in &gt;or=1 additional vascular beds: 36% <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>; 10% PAD and 6% both </plain></SENT>
<SENT sid="7" pm="."><plain>The prevalence of risk factors at baseline was higher in the <z:hpo ids='HP_0002326'>TIA</z:hpo> subgroup than in the <z:hpo ids='HP_0001297'>stroke</z:hpo> group: treated <z:hpo ids='HP_0000822'>hypertension</z:hpo> (83.5/82.0%; p = 0.02), body mass index &gt;or=30 (26.7/20.8%; p &lt; 0.0001), <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> (65.1/52.1%; p &lt; 0.0001), <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (14.7/11.9%; p &lt; 0.0001) and <z:e sem="disease" ids="C0007273" disease_type="Disease or Syndrome" abbrv="">carotid artery disease</z:e> (42.3/29.7%; p &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> patients received antiplatelet agents (81.7%), oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> (17.3%), <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering agents (61.2%) and <z:chebi fb="0" ids="35674">antihypertensives</z:chebi> (87.9%), but guideline treatment targets were frequently not achieved (54.5% had elevated blood pressure at baseline, while 4.5% had untreated <z:mp ids='MP_0002055'>diabetes</z:mp>) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: A high percentage of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> patients have additional atherothrombotic disease manifestations </plain></SENT>
<SENT sid="10" pm="."><plain>The risk profile puts <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> patients, especially the <z:hpo ids='HP_0002326'>TIA</z:hpo> subgroup, at high risk for future atherothrombotic events </plain></SENT>
<SENT sid="11" pm="."><plain>Undertreatment is common worldwide and adherence to guidelines needs to be enforced </plain></SENT>
</text></document>